Announcement PDF ASX RELEASE 3 October 2023 Date of AGM & Closing Date for Director Nominations Paradigm Biopharmaceuticals Ltd (ASX:PAR) (“Paradigm” or “the Company”), a late-stage drug development company, advises that, in accordance with ASX Listing Rule 3.13.1, its next Annual General Meeting (AGM) will be held at 9:00am (AEDT) on Wednesday 29 November 2023. In addition, the closing date for the receipt of nominations from persons wishing to be considered for election as a director is Tuesday 10 October 2023. Any nominations must be received in writing no later than 5.00pm (AEDT) on 10 October 2023 at the Company’s registered office. Shareholders will be advised of further details regarding the AGM in a separate Notice of Meeting, which will be provided to shareholders shortly. The Notice of Meeting will also be available on the ASX Company Announcements Platform and the Company’s website at https://paradigmbiopharma.com/. About Paradigm Biopharmaceuticals Paradigm Biopharmaceuticals LTD (ASX:PAR) is a late-stage drug development company driven by a purpose to improve patients’ health and quality of life by discovering, developing, and delivering pharmaceutical therapies. Paradigm’s current focus is developing injectable (subcutaneous) pentosan polysulfate sodium (iPPS) for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of iPPS, such as in osteoarthritis (phase 3) and mucopolysaccharidosis (phase 2). Authorised for release by the Company Secretary on behalf of the Board. To learn more please visit: https://paradigmbiopharma.com/ FOR FURTHER INFORMATION PLEASE CONTACT: Simon White Director of Investor Relations Tel: +61 404 216 467 Paradigm Biopharmaceuticals Ltd ABN: 94 169 346 963 Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA Email: investorrelations@paradigmbiopharma.com